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Abstract
Introduction: Globally, transgender (‘‘trans’’) women are one of the key populations most disproportionately impacted by HIV.
Pre-exposure prophylaxis (PrEP) is the newest and most promising biomedical HIV prevention intervention to date. This paper
reviews relevant literature to describe the current state of the science and describes the potential role of PrEP among trans
women, including a discussion of unique considerations for maximizing the impact of PrEP for this vulnerable population.
Methods: Available information, including but not limited to existing scientific literature, about trans women and PrEP was
reviewed and critiqued based on author expertise, including PrEP clinical trials and rollout.
Results: To date, PrEP demonstration projects and clinical trials have largely excluded trans women, or have not included them in
a meaningful way. Data collection strategies that fail to identify trans women in clinical trials and research further limit the
ability to draw conclusions about trans women’s unique needs and devise strategies to meet them. Gender-affirming providers
and clinic environments are essential components of any sexual health programme that aims to serve trans women, as they will
largely avoid settings that may result in stigmatizing encounters and threats to their identities. While there is currently no
evidence to suggest drug-drug interactions between PrEP and commonly used feminizing hormone regimens, community
concerns about potential interactions may limit interest in and uptake of PrEP among trans women.
Conclusions: In scaling up PrEP for trans women, it is essential to engage trans communities, utilize trans-inclusive research and
marketing strategies and identify and/or train healthcare providers to provide gender-affirming healthcare to trans women,
including transition-related care such as hormone provision. PrEP implementation guidelines must consider and address trans
women’s unique barriers and facilitators to uptake and adherence.
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Introduction
Transgender (‘‘trans’’) women are disproportionately im-
pacted by HIV worldwide [1]. A meta-analysis found that trans
women are 49 times more likely to be living with HIV than the
general population, with an estimated global pooled preva-
lence of 19% [2]. This overwhelming disparity calls attention
to the urgent need for effective HIV prevention strategies that
meet the unique needs of this population. The World Health
Organization’s Consolidated Guidelines for Key Populations
state ‘‘the high vulnerability and specific health needs of trans
people necessitate a distinct and independent status in the
global HIV response’’ [1].This paper reviews relevant literature
to describe the current state of the science and the potential
role of pre-exposure prophylaxis (PrEP) among trans women,
including a discussion of unique considerations for maximizing
the impact of PrEP for this vulnerable population.
Transgender identities are diverse and nuanced, varying
between and within cultures. The terms ‘‘transgender’’ and
‘‘trans’’ are often used as umbrella terms to describe people
whose gender identity differs from the sex assigned at birth;
however, many people included in discussions of trans people
may use other or additional terms to describe themselves [3]
and/or may identify outside of the typical male/female
binary altogether.While the terms ‘‘transgender’’ and ‘‘trans’’
are more common in Western cultures, they are also gaining
more widespread use as the movement for transgender
human rights becomes globalized. Some cultures acknowl-
edge genders outside of the binary, sometimes referred to
as ‘‘third gender’’ classifications, such as Native American
berdaches or ‘‘Two Spirit’’ people, or the Fa’afafine of Samoa.
Other terminology used to describe trans people includes the
terms mak nyah in Malaysia [4], kathoey in Thailand [5], hijra
in India, Bangladesh and Pakistan [68], waria in Indonesia
[9], rae rae and mahu in French Polynesia [10] and travesti in
South America [11].
Furthermore, there is great variation in access to healthcare,
human rights and availability of transition-related medical
care. Thus no singular, monolithic transgender identity or
classification exists. For the purposes of this discussion, the
terms ‘‘transgender’’ or ‘‘trans’’ women describe people who
share a common experience of being assigned male sex at
birth, but who identify as female, transgender or trans female,
or another identity along the trans-feminine spectrum, while
acknowledging that cultural context introduces variability
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along many dimensions of life experience. At this time, there is
limited information about the feasibility, acceptability and
effectiveness of PrEP for trans women cross-culturally. Much
of the existing information comes from one international
clinical trial where enrolment of trans women was limited to a
few sites and from regional studies in North and South America
and Thailand.
Despite contextual differences, trans-related stigma (‘‘trans-
phobia’’) is pervasive cross-culturally and can limit opportu-
nities and access to resources in a number of critical life
domains (e.g. employment, healthcare), persistently affecting
the physical and mental health of trans people, including
HIV [12]. Trans women face unique challenges related to sex
work and need for gender affirmation that can increase their
vulnerability to HIV [1315]. Worldwide, trans women who
engage in sexworkexperience unique structural, interpersonal
and individual vulnerabilities that contribute to a dispropor-
tionate risk for HIV compared with non-trans (or ‘‘cisgender,’’
a term often used to describe people who do not identify as
transgender) male and female sex workers [16,17]. In addition,
there is a clear need for increased HIV testing among trans
women [18], with some preliminary evidence for feasibility
and acceptability of self-testing [19].While rates of HIV among
trans men are lower than those of trans women, there is
evidence of HIV risk behaviours among trans men who have
sex with men (MSM) and subsequent speculation that HIV
rates may increase among this population in the years to come
[20,21].
Recently, PrEP has garnered a great deal of interest and
attention as the newest and most promising biomedical HIV
prevention intervention developed and tested to date.The first
clinical trial of PrEP (iPrEx) included both high-risk MSM and
trans women; risk of HIV acquisition was reduced by 44% [22].
However, a sub-analysis of the iPrEx data found no effective-
ness (based on intention to treat rather than whether PrEP
was actually used) among the sub-group of trans women in
the study [23]. As with MSM, all of the trans women who
became infected had low or undetectable drug concentra-
tions, suggesting use of fewer than four tablets per week. The
detection of PrEP drug concentrations among trans women
using feminizing hormones was similar to trans women not
using hormones and MSM for the first 12 weeks of the study,
then dropped off afterward. This pattern suggests that long-
term adherence was the issue rather than a drug-drug
interaction. Lower levels of uptake and adherence among
trans women compared to MSM likely contributed heavily to
the differential rates of efficacy, but there have not yet been
pharmacokinetic studies to rule out a drug-drug interaction
of PrEP with hormones [24]. To date, iPrEx is the only clinical
trial of PrEP for HIV prevention with confirmed enrolment
of trans women [25]. Trans women are eligible for enrolment
in the majority of PrEP studies that enrol MSM [26], includ-
ing Ipergay [27] and HPTN 067 ADAPT (R. Grant, Interna-
tional AIDS Conference 2015, Vancouver). However, very
few if any trans women have actually been enrolled in these
trials [28].
PrEP demonstration projects to date have reported low or
unclear levels of enrolment of trans women [28,29].The Demo
Project, a three-city PrEP demonstration project conducted in
the United States, is usually described as a cohort of MSM and
trans women [28]. However, the project enrolled only seven
trans women across all three sites, out of a total of 557
enrolled participants. Due to low enrolment numbers, it is
impossible to make comparisons or draw conclusions about
unique correlates of uptake and adherence among trans
women. Furthermore, there are currently no guidelines for
PrEP demonstration projects that provide specific considera-
tions for provision of PrEP to trans women. The World Health
Organization guidance mentions trans women but there is
no consideration of specific needs among this population.
Guidance on PrEP from the US Centers for Disease Control
and Prevention makes no mention of trans women whatso-
ever [30,31]. In 2016, the California HIV/AIDS Research
Program funded the first large-scale PrEP demonstration
projects specifically for trans populations, including trans
men [32]. As this funding is recent, there are not yet any
data available.
PrEP awareness and acceptability among trans
women
Low levels of PrEP awareness among trans women have been
noted in San Francisco [33], Brazil [15], Chicago and Boston
[34]. Some studies, however, have found that while PrEP
awareness is low among trans women, interest in PrEP is high
once patients are informed [34,35]. A study of 107 trans
women and 131 MSM in Chang Mai, Thailand, found similar
levels of PrEP acceptability between the two groups. However,
significant differences between MSM and trans women were
found in sexual behaviours, patterns of medication use and
correlates of PrEP acceptability. For example, trans women
were more likely to exclusively engage in receptive anal sex,
which may impact their HIV risk perception and thus their
willingness to take PrEP [36].
PrEP may be an empowering tool for trans women who are
engaged in sex work to increase their sense of personal
control over HIV prevention. Sex work is more prevalent in
the lives of trans women due to social and economic
marginalization, and PrEP programmes seeking to serve trans
women may benefit from incorporating messaging about
HIV prevention during sex work [35]. Trans women may have
significant mistrust of the medical community’s awareness of
transgender-specific health concerns [37]. These concerns are
well founded given that half of a large sample of trans people
in the United States reported having to teach their provider
about their own care [38]. Concerns about potential negative
effects of PrEP on gender-affirming hormone therapy may
also represent a barrier to PrEP acceptability [35]. An interim
analysis of 608 HIV-positive trans women of colour in care at
several clinics in the United States found that the percep-
tion of a negative effect of antiretroviral drugs on gender-
affirming hormone therapy was associated with an odds ratio
of 2.88 for having taken a higher dose of hormones than
prescribed in the prior six months [39]. This finding could
suggest that there is a concern regarding a negative action of
ART medications on hormones, which may for some result in
avoidance of or non-adherence to PrEP.
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Building trust in PrEP: gender-affirming clinical
practices
Gender-affirming healthcare includes using patients’ preferred
names and pronouns, respecting diversity in patients’ gender
identities and expressions, and generally creating safe spaces
for trans patients to be themselves, in addition to the provision
of hormone and other gender-affirming medical care. Provi-
ders and clinical staff should be adequately trained to provide a
safe, welcoming and culturally appropriate environment for
trans people to seek care. This includes the provision of safe
restrooms, comfort with and use of appropriate trans-related
terminology, and the display of trans-affirming visuals and
health-related information in waiting rooms, as appropriate.
Gender-affirming hormone therapy has been found to
improve quality of life and social functioning and to reduce
levels of anxiety and depression [4042]. Bundling of a
desired service such as gender-affirmingmedical interventions
with HIV prevention efforts likely has synergistic value [43].
Engaging trans women in both behavioural and biomedical HIV
prevention activities at the time and location of provision of
gender-affirming hormone therapy fits well into the bundling
model. Access to gender-affirming hormones also represents
a potential intervention within several constructs of the
Model of Gender Affirmation, including reducing barriers
to healthcare, reduced body shame, increased access to
gender affirmation and reduced use of street hormones or
silicone [14].
It is essential to train healthcare providers to provide
gender-affirming healthcare to trans women, including
hormone provision. It cannot be assumed automatically
that providers and clinic staff who serve MSM are equipped
to recruit, retain and provide care to trans women [37].
Programming and services that are designed for MSM or
offered through clinics that primarily serve MSM often do
not meet the needs of trans women, as many trans women
do not feel comfortable accessing programmes and services
designed for men and these services do not address their
unique life context [44]. In San Francisco, trans women
described the importance of finding trans-competent, gender-
affirming providers as a powerful facilitator to increasing the
acceptability of PrEP [35].
While it is important to continue to develop trans-specific
services, existing programmes should also be expanded to
include effective programming for trans women. In low- and
middle-income countries that do not have the resources to
justify funding and developing separate trans-specific pro-
gramming, health ministries should possess basic knowledge
on effectively serving local communities of transwomen at risk
for acquiring HIV. For example, offering PrEP and other sexual
health services to trans women through services oriented to
cisgender women represents another potential approach.
Many women-focused sexual health services are seeking to
be more trans-inclusive, but there are currently no data or
guidance available to support these efforts. Contextually
situated psychosocial drivers of HIV risk among many trans
women are more similar to those of non-trans women than
those of men. These psychosocial drivers include experiences
of trauma, domestic and sexual violence, misogyny, survival
sex work, sexual objectification and unequal power in relation-
ships to negotiate safer sex [37,38,45,46].
Where transition-related services such as hormones are
not available, clinicians should still provide care that is
gender affirming and assist the person in accessing transition-
related care services when possible. Assistance in obtain-
ing legal identification, health insurance and identifying
trans-specific support services can all be helpful. If the patient
is taking hormones obtained in other ways (i.e. on the street
or Internet), clinicians can support a person’s transition by
checking hormone blood levels and providing education about
safe hormone use.
PrEP services are amenable to algorithmic care protocols,
making such services implementable in a large variety of
clinical settings including sexual health clinics, family practice
clinics, reproductive health clinics, community clinics and
student clinics, in both small and large practices. However,
clinical familiarity with PrEP protocols and sexual health
testing and management is currently limited. A greater
limitation arises from the lack of familiarity with best practices
for gender-affirming medical care, such that finding a health-
care provider who is able to provide both PrEP and gender-
affirming care has been difficult for trans people. As such,
another approach to improving PrEP uptake and adherence
in trans women is by expanding PrEP-related knowledge and
skill among existing providers of gender-affirming clinical
services.
Segmentation of sexual health services according to the
gender binary is another barrier. Sexual health services
oriented exclusively for MSM frequently do not provide
services required by trans men, including cervical cancer
screening, pregnancy tests and skill in prescribing hormonal
contraception. Similarly, practices that are oriented mainly to
the needs of cisgender women, such as OB/GYN practices,
may not be familiar with evaluation and management of
trans women or men. Expanding gender-specific services to
include trans people is crucial to improving sexual health
within these communities.
Further, trans women may experience unique barriers
to obtaining healthcare. In addition to increased rates of
unemployment, which can result in un- or under-insurance,
trans women may avoid enrolling in safety net insurance
programmes or visiting clinics due to lack of legal identification
documents that reflect their affirmed gender. Mismatches
between the sex listed on legal documents and insurance
policies may result in a denial of insurance claims. While
insurance coverage should not determine access to PrEP, drug
costs can be a major barrier to PrEP rollout, especially in low-
and middle-income countries [47].
Building evidence for PrEP: trans-inclusive
research strategies
Uniform and universal collection of gender identity data is an
essential structural-level HIV prevention intervention in trans
populations. Failure to identify, describe and quantify trans
populations results in an invisibility at the institutional level,
with resultant exclusion from policymaking, funds allocation
and research activities [44]. Trans women, their advocates
and public health researchers have issued a strong call for the
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disaggregation of trans women from MSM in HIV prevention
programming and research [2,17,48], as the importance
of incorporating gender-affirming practices in addressing
HIV among trans women is becoming increasingly recognized
[14,37].
Ongoing challenges in collecting valid data on trans people
and HIV include cultural variation in language used to describe
trans people and lack of standardized measurements [49].
The use of the two-step method for the collection of gender
identity data has been recommended by a wide range of
experts and institutions [50,51]. This method includes query-
ing both gender identity (using a wide range of locally
appropriate options) and birth-assigned sex. Trans people are
identified as thosewith a gender identity that differs from their
birth-assigned sex. Failure to use the two-step method can
result in some trans people responding to a single question on
sex/gender as either ‘‘male’’ or ‘‘female’’ rather than ‘‘trans-
gender’’; a study comparing these two methods found the
two-step method doubled the number of trans people identi-
fied within a population [52]. The consequences of a failure
to accurately record gender identity were described in the
aforementioned sub-analysis of trans participants in the iPrEx
trial, inwhich amore in-depth analysis using surrogatemarkers
revealed that 13% of trans participants had not been identified
in the original analysis [24,53].
Low enrolment of trans participants in clinical trials of PrEP
to date can likely be attributed to the passive inclusion of trans
women without implementation of any trans-specific recruit-
ment strategies or proactively training staff to provide care
that is sensitive and supportive to trans people. Enrolment of
trans women in future trials can be improved by carefully
planning study outreach efforts and intentionally designing
recruitment and retention strategies to address the unique
needs and potential concerns of trans women. Designing
gender-affirming strategies, such as specifically addressing
and representing trans women in recruitment materials, hiring
trans study staff, offering gender-affirming healthcare and
ensuring the representation of trans people at all levels of
the project, such as on advisory boards, study staff and
involving trans people in the design of the study, can all help
improve enrolment of trans people in clinical trials and future
PrEP demonstration projects [54].
Building demand for PrEP: community
engagement and empowerment
While some initial research has shown that there is interest
in PrEP among trans women when they are aware of it,
demand for PrEP among transwomen is yet unproven. Building
demand for PrEP will be an important first step in implementa-
tion, and community engagement in this process will be
crucial. Community mobilization strategies are particularly
effective in increasing empowerment and decreasing stigma
among marginalized populations and in disseminating novel
information via trusted social networks [55]. Social marketing
strategies should emphasize gender-affirming, sex-positive
messaging about the potential benefits of PrEP, such as in-
creased sexual pleasure and intimacy, increased sense of safety
during sex, decreased HIV-related anxiety, decreasing stigma-
tizing attitudes toward HIV-positive partners, increased sense
of community and increased self-efficacy for HIV prevention
[56]. PrEP can empower the individual to take control of
preventing their own acquisition of HIV without relying on
prevention strategies often controlled by one’s partner (i.e.
condom use), and the disclosure of one’s own decision to take
PrEP is also a personal choice. PrEP champions, or individuals
who are willing to publicly share about their own positive
experiences with PrEP, may be particularly powerful sources of
support and builders of trustwhen they come fromwithin local
trans communities.
Involvement of trans women in the design and develop-
ment of PrEP studies and programmes that aim to include
them is crucial to successful enrolment. This helps to ensure
that the messaging, environment and questions being asked
are relevant to trans women’s unique needs and concerns.
Patient decision-making tools and adherence support strate-
gies should be designed specifically for trans women with
their input, rather than adapted from strategies that were
designed for MSM.
Biomedical considerations
No evidence currently exists to suggest that PrEP interacts with
commonly used feminizing hormone regimens, and evidence
from studies of antiretroviral interactions with hormonal
contraceptives has been reassuring [57]. However, there
have not yet been any pharmacokinetic studies of these
potential drug-drug interactions with trans women. Studies
of interactions between combined oral contraceptives and
antiretroviral medications have generally not indicated nega-
tive interactions between the classes [58]. Important differ-
ences exist in the context of transgender care,where a range of
oestrogens are used, most commonly bioidentical 17-beta
estradiol, in contrast to the synthetic ethinyl estradiol used in
oral contraceptives. Furthermore, use of progestogens is
inconsistent among trans women. Further study is needed to
explore potential interactions between PrEP medications and
commonly used gender-affirming hormones. Also requiring
exploration are any changes in the anal epithelium in response
to hormone therapy, as well as considerations in trans women
who have undergone a penile inversion vaginoplasty, in which
penile and scrotal skin is inverted to create a vagina and vulva,
possibly with the use of urethral mucosa. The risks of HIV
transmission via these organs, as well as the risks and rates
of ulcerative genital infections and local concentrations of
PrEP medication are unknown and require further study [17].
As previously described, compared with MSM, trans
women in the iPrEx study had lower concentrations of active
metabolites of tenofovir disoproxil fumarate (TDF) and
emtricitabine [53]. Concentrations of PrEP medications were
especially low among trans women reporting use of feminizing
hormones, which may reflect less PrEP use or a drug-drug
interaction.While there are no systemic drug-drug interactions
between TDF and oral contraception, there are known
interactions at the level of drug transporters between these
classes of medications that could affect drug concentrations
in target tissues [59]. Drug-drug interactions between TDF
and either natural oestrogens or anti-androgenic agents used
for gender-affirming hormone therapy among trans women
have not been studied. Drug-drug interactions between
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emtricitabine and any of these medications have also not
been studied.
Conclusions
The future of PrEP among trans women relies on reversal of
the relative invisibility of trans women in research and clinical
services that inform the structure of programming and access
to PrEP. Guidelines developed for the implementation of
PrEP must consider the unique barriers to and facilitators of
uptake among trans women. Risk assessment tools, adher-
ence support and retention strategies are currently being
developed without consideration of issues unique to trans
women and are not validated for use with trans women [60].
Structural interventions are needed, such as comprehensive
provider training programmes for all level staff to better
serve the needs of trans women and increase service
utilization and improve wellbeing, while effecting lasting
institutional change [61]. It is vitally important that PrEP
messaging and information be delivered via trans-specific
networks with the unique concerns and life contexts of trans
women in mind. Community-based strategies, such as
community mobilization to increase knowledge and trust of
information about PrEP among trans women, should be
explored.
Because trans women may prioritize hormone therapy
over other healthcare [35,37], bundling of PrEP with gender-
affirming hormones may help address this barrier to PrEP
uptake and adherence by both serving as a venue for
distribution of accurate information regarding drug interac-
tions and co-packaging of hormones and PrEP medication to
overcome any barriers relating to increased pill burden.
Multimodal interventions are recommended to increase PrEP
uptake and provide adherence support, and all interventions
must consider culturally unique barriers to healthcare access
and adherence to maximize effectiveness with trans women
[30,60,62]. PrEP can be a cost-effective addition to compre-
hensive sexual health programmes when people with the
highest risk of acquiring HIV, such as trans women, are given
priority of access [47]. PrEP may also provide additional
benefits above and beyond HIV prevention, such as commu-
nity empowerment and engaging previously marginalized
communities of trans women into healthcare. The mean-
ingful engagement and inclusion of trans women in the
development of PrEP rollout strategies and the disaggrega-
tion of trans women from MSM in ongoing PrEP research and
programming are essential initiatives to promote this highly
promising HIV prevention tool among a key population that
to date has been largely overlooked.
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